الفهرس 
Introduction:Only 14 pages are availabe for public view
 |  | from | 212 |  |  |
| | | from | 212 | | |
Abstract
The topical application of ethosomal gel of metformin has a significant effect on treating melanoma cancer. By (BB) design enables high encapsulation efficiency, optimum particle size, high zeta potential, and high drug release.
The formula composed of 2.083% w/w of lecithin, 0.524% w/w of cholesterol, 37.495% v/v of ethanol, and 0.2% w/w of stearylamine was chosen as an optimum formula because it achieved the maximum desirability index (0.811). The selected optimum formula (13) displayed a %EE of 98.4±0.35%, a VS of 124±14.2 nm, a release of 55±0.98%, a permeability of 969±13.2μg/cm2 after 8h, and the ZP of the optimum formula was measured and found to be equal -60±1.4mV which provided good stability.
Ethanol significantly affects skin penetration, decreasing particle size, and induction of negative charge. Adding IPA with ethanol to form ethosomes increases ability of ethanol to solubilize lecithin, which leads to increased stability and effectiveness of ethosomes vesicles. IPA also decreases the VSof a vesicle, which increases EE% and allows the metformin to be released for an extended period; this is the goal of our research.
Stearylamine and cetrimide can induce the sustained releasing state in ethosomal formulations. But Stearylamine has an advantage over cetrimide in maintaining vesicle size, zeta potential, and better drug release.
In in-vivo tests, metformin which loaded on ethosomes achieve the most decreasing in width and length of lesions which obtain the ability of metformin to enhance the skin cancer recovery.